Literature DB >> 8239622

Ofloxacin susceptibilities of 5,667 Neisseria gonorrhoeae strains isolated in Hong Kong.

K M Kam1, K K Lo, C F Lai, Y S Lee, C B Chan.   

Abstract

Of 5,667 strains of Neisseria gonorrhoeae isolated from the Government Social Hygiene (sexually transmitted disease) Clinics in Hong Kong from 1990 to 1992, there was a trend toward an increase in the percentage of strains resistant in vitro to 0.01 and 0.1 microgram of ofloxacin per ml, with 54.3 and 5.5% resistant strains, respectively, in January 1990, rising to 95.3 and 41.5%, respectively, in December 1992. The percentage of strains for which the MIC is > 1 microgram/ml remains stable, and no clinical failure has yet been seen. This trend of decreasing susceptibility warrants close monitoring when ofloxacin is used as first-line treatment for gonorrhea.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239622      PMCID: PMC188111          DOI: 10.1128/AAC.37.9.2007

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains.

Authors:  J M Covino; M Cummings; B Smith; S Benes; K Draft; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Effectiveness of ofloxacin in the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae cervical infection.

Authors:  S Faro; M G Martens; M Maccato; H A Hammill; S Roberts; G Riddle
Journal:  Am J Obstet Gynecol       Date:  1991-05       Impact factor: 8.661

3.  4-Quinolone-resistant Neisseria gonorrhoeae in the United Kingdom.

Authors:  W R Gransden; C Warren; I Phillips
Journal:  J Med Microbiol       Date:  1991-01       Impact factor: 2.472

4.  Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection.

Authors:  J R Black; J M Long; B E Zwickl; B S Ray; M S Verdon; S Wetherby; E W Hook; H H Handsfield
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Effect of ofloxacin in the treatment of genitourinary tract infection with Ureaplasma urealyticum.

Authors:  N Kawamura; N Nakajima; H Hoshino; M Tanaka; A Koinuma
Journal:  Hinyokika Kiyo       Date:  1989-12

6.  Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease.

Authors:  B E Batteiger; R B Jones; A White
Journal:  Am J Med       Date:  1989-12-29       Impact factor: 4.965

7.  Treatment of nongonococcal urethritis: comparison of ofloxacin and erythromycin.

Authors:  H H Ibsen; B R Møller; L Halkier-Sørensen; E From
Journal:  Sex Transm Dis       Date:  1989 Jan-Mar       Impact factor: 2.830

8.  Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: response of chlamydia-positive and chlamydia-negative forms.

Authors:  V Chandeying; S Sutthijumroon; S Tungphaisal
Journal:  J Med Assoc Thai       Date:  1989-06

9.  [Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis].

Authors:  Y Kumamoto; S Sakai; T Hirose; T Tsunekawa; T Machida; H Kiyota; T Okazaki; H Kishi; E Higashihara; Y Aso
Journal:  Jpn J Antibiot       Date:  1988-10

10.  Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand.

Authors:  T E Clendennen; P Echeverria; S Saengeur; E S Kees; J W Boslego; F S Wignall
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  6 in total

1.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

2.  Quinolone Resistance in Neisseria gonorrhoeae.

Authors:  Janine R. Tompkins; Jonathan M. Zenilman
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 3.  Quinolones in sexually transmitted diseases. Global experience.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Detection of quinolone-resistant Neisseria gonorrhoeae.

Authors:  K M Kam; P W Wong; M M Cheung; N K Ho
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

5.  Rapid decline in penicillinase-producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance.

Authors:  K M Kam; K K Lo; N K Ho; M M Cheung
Journal:  Genitourin Med       Date:  1995-06

Review 6.  Fluoroquinolone resistance in Neisseria gonorrhoeae.

Authors:  J S Knapp; K K Fox; D L Trees; W L Whittington
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.